New research suggests that there may not be a correlation between the diabetes drug Byetta and acute pancreatitis, raising questions about whether the drug caused prior reports of severe necrotizing…
According to Amylin Pharmaceuticals, Inc., the new long-acting version of their diabetes drug Byetta does not have the same link to thyroid cancer recently associated with Novo Nordisk’s Liraglutide, a…
Amylin Pharmaceuticals, Inc. and Eli Lilly and Co. said this week that a new meta-analysis of clinical data for their diabetes drug Byetta indicates that the injection does not increase…
Amylin Pharmaceuticals has reported a larger fourth quarter loss, which they indicate was caused in part by Byetta pancreatitis problems that have caused sales to decline sharply for their diabetes…
According to a statement released today by Amylin Pharmaceuticals and Eli Lilly, the FDA’s review of their application to allow use of Byetta as a stand-alone therapy for treatment of…
The FDA has rejected data submitted by Amylin Pharmaceuticals for a longer-acting Byetta, which will likely delay the new version of their diabetes drug. This is another blow to Amylin,…
Over the eight weeks since concerns first emerged about a potential link between the Byetta pen and pancreatitis, the stock price for the drug’s maker, Amylin Pharmaceuticals, has fallen dramatically.
In a conference call late Monday, Eli Lilly & Co. and Amylin Pharmaceuticals, Inc. indicated that they have notified the FDA about four more deaths from pancreatitis among users of…
A diabetic patient who developed pancreatitis as a side effect of Byetta has filed a lawsuit in a California state court. This is reportedly the first Byetta lawsuit to be…
On August 18, 2008, the FDA issued an alert to healthcare providers about six additional cases of necrotizing or hemorrhagic pancreatitis among users of Byetta, two of which have resulted…
